Lupin received USFDA approval for generic Pitolisant Tablets, strengthening its US portfolio and specialty generics presence. Shares remain technically weak despite strong long-term returns,.
Syndicated via official news feed
Syndicated feed content with full publisher credit.
Continue reading verified coverage and related developments on this desk.
Latest developments and reports from the desk
Latest fundraising values the six-year-old company at about $650mn as it aims to be ‘daily luxury brand’
Stéphane Boujnah has obsessively chased acquisitions to compete with larger rivals
As governments borrow more, the buyers of their debt are changing